Reference intervals for C-peptide and insulin derived from a general adult Danish population

Accepted Manuscript Reference intervals for C-peptide and insulin derived from a general adult Danish population

Pia Bükmann Larsen, Allan Linneberg, Torben Hansen, Lennart Friis-Hansen PII: DOI: Reference:

S0009-9120(16)30228-4 doi: 10.1016/j.clinbiochem.2016.12.004 CLB 9445

To appear in:

Clinical Biochemistry

Received date: Revised date: Accepted date:

2 September 2016 9 December 2016 12 December 2016

Please cite this article as: Pia Bükmann Larsen, Allan Linneberg, Torben Hansen, Lennart Friis-Hansen , Reference intervals for C-peptide and insulin derived from a general adult Danish population. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Clb(2016), doi: 10.1016/ j.clinbiochem.2016.12.004

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Reference intervals for C-peptide and insulin derived from a general adult Danish population Pia Bükmann Larsen1, Allan Linneberg2,3,4, Torben Hansen5, Lennart Friis-Hansen6,7

PT

1 Department of Clinical Biochemistry, Slagelse Hospital, Slagelse, Denmark

RI

2 Research Centre for Prevention and Health, the Capital Region of Denmark, Copenhagen,

SC

Denmark

NU

3 Department of Clinical Experimental Research, Rigshospitalet, Denmark

4 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of

MA

Copenhagen, Copenhagen, Denmark

5 Section of Metabolic Genetics, Faculty of Health Sciences, University of Copenhagen,

PT E

D

Copenhagen, Denmark

6 Department of Clinical Biochemistry, Nordsjællands Hospital, Hillerød, Denmark

CE

7 Steno Diabetes Center, Copenhagen, Denmark

AC

Word count: Abstract 250 words, text 3,025 words, 37 references, 2 figures, 7 tables, no supplementary tables.

Running title: C-peptide and insulin reference intervals (41 characters)

Correspondence: Lennart Friis-Hansen Department of Clinical Biochemistry Nordsjællands Hospital Denmark [email protected]

ACCEPTED MANUSCRIPT Abstract Background: Despite international efforts to standardize C-peptide and insulin calibrators and immunoassays, platform dependent differences still exist, and platform specific reference intervals are hence needed for correct interpretation. We therefore wanted to establish traceable reference

PT

intervals for C-peptide and fasting insulin. Methods: In 623 consecutively recruited participants, insulin and C-peptide were measured using

RI

the Cobas e411 (Roche Diagnostics, Switzerland). Participants with diabetes were excluded

SC

(fasting Glucose ≥ 7.0 mmol/l or HbA1c ≥ 6.5% / ≥ 48 mmol/l) and reference intervals were

NU

calculated with and without the inclusion of persons who were prediabetic, according to two definitions (The World Health Organization (WHO) and American Diabetes Association (ADA)).

MA

To ensure the correctness of calibration, the control pools were analyzed by a reference laboratory. The reference intervals were calculated according to the IFCC guidelines, using the RefVal

D

software (Solberg, Oslo, Norway).

PT E

Results: Comparison of our results with those from the reference laboratory revealed equivalence for C-peptide results whereas the insulin determined on the Cobas e411 assay were 15-20 %

CE

higher. The difference is attributed to an incorrect conversion factor for converting from activity to metric units. The Cobas e411 assay uses the factor 6.945 for converting from U/ml to pmol/L. This

nmol/IU.

AC

is in disagreement with the biological activity of insulin which is 166.8 x 106 IU/mol or 6.00

Conclusion: We successfully established reference intervals for C-peptide and insulin for nondiabetic and prediabetic participants. The reference intervals for fasting C-peptide and fasting insulin are ready for implementation. A recertification of the insulin standards is needed.

ACCEPTED MANUSCRIPT Keywords:

insulin,

C-peptide,

reference

values,

diabetes

mellitus,

AC

CE

PT E

D

MA

NU

SC

RI

PT

Radioimmunoassay

prediabetic

state,

ACCEPTED MANUSCRIPT Abbreviations: SDC: Steno Diabetes Center DEKS: Dansk Institut for Ekstern Kvalitetssikring for laboratorier i Sundhedssektoren/Danish Institute for External Quality Assurance for laboratories in the Health sector IRP: international reference preparation

PT

RI: reference interval

RI

DM: diabetes mellitus

SC

DM1: diabetes mellitus type 1 DM2: diabetes mellitus type 2

NU

PDM: prediabetes FPG: fasting plasma glucose

MA

HbA1c: hemoglobin A1c BMI: body mass index

BF%: body fat percentage

PT E

WHR: waist-to-hip ratio

D

WC: waist circumference

CE

WHO: World Health Organization

ADA: American Diabetes Association

AC

MetS: metabolic syndrome

UofMN: University of Minnesota

ACCEPTED MANUSCRIPT Author Contributions: study concept and design (MFR, TH, AL, LFH)

•

acquisition of data (HN, AL, LFH)

•

analysis and interpretation of data (PBL, LFH)

•

drafting of the manuscript (LFH, PBL)

•

critical revision of the manuscript for important intellectual content (PBL, AL, TH, LFH)

•

statistical analysis (LFH, PBL)

•

obtained funding (AL, LFH, MFR)

•

administrative, technical, or material support (LFH)

•

study supervision (LFH, TH)

AC

CE

PT E

D

MA

NU

SC

RI

PT

•

ACCEPTED MANUSCRIPT

Introduction.

Human insulin is a 5.8 kDa polypeptide produced in the islets of Langerhans, the endocrine part of the pancreas. Glucose is the most important regulator of insulin secretion. Insulin is an anabolic

PT

hormone that lowers blood glucose through stimulation of synthesis of glycogen, proteins and

RI

lipids and inhibition of lipolysis [1]. The 81 amino acid proinsulin peptide consists of three domains: an amino-terminal B-chain, a carboxy-terminal A-chain and a connecting peptide in the

SC

middle, known as the C-peptide. During passage through the endoplasmic reticulum, the precursor

NU

folds and the prohormone convertases PC1/3 and -2 subsequently excise the C-peptide, generating the mature form of insulin and C-peptide [2]. C-peptide is stored in beta cells and released by

MA

active secretion in equimolar amounts to insulin [3]. Only fully matured insulin from which Cpeptide has been removed can interact with the insulin receptor [4]. The conversion of proinsulin is

D

almost complete, thus only a small amount of proinsulin is found in the blood. Insulin is primarily

PT E

degraded in the liver, whereas 85 % of C-peptide, in contrast, is cleared from circulation by renal filtration [5]. Furthermore, the half-life of C-peptide is longer than insulin (20-30 and 3-5 minutes,

CE

respectively). Hence, the concentration of C-peptide is three to six times higher than the concentration of insulin. The rate of elimination of insulin depends on multiple metabolic

AC

processes leading to great variety in plasma level, whereas the plasma concentration of C-peptide varies less. Therefore, the plasma C-peptide concentration is a better measure for assessing insulin secretion [1].

In the clinic, measurements of C-peptide are mainly used to distinguish between diabetes mellitus (DM) type 1 (DM1) and 2 (DM2). DM is defined as “a group of diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both” [6]. DM1 is caused by beta-cell destruction and leads to absolute insulin deficiency. In contrast, DM2 results

ACCEPTED MANUSCRIPT from insulin resistance and a progressive insulin secretory defect [7]. Prediabetes (PDM) indicates an increased risk of developing diabetes. Prediabetic patients by definition have impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) which are associated with the metabolic syndrome (MetS) [8]. MetS is a group of risk factors together linked to an increased risk of DM2 and cardiovascular disease: obesity/central obesity, insulin resistance, hypertension and

PT

dyslipidemia (hypertriglyceridemia) [9]. Abdominal obesity or adiposity is the key clinical feature

SC

RI

in MetS and seems to precede the other risk factors [10].

Both insulin and C-peptide are usually measured using antibody based assays. In fact, the

NU

radioimmunoassay (RIA) - invented by Yalow and Berson more than fifty years ago - was first used to quantify insulin [11]. Despite this, the standardization of the calibrators, assays and

MA

standardization of reference intervals is still not complete [12]. An Insulin Standardization Workgroup was established by ADA in 2004 to address the issue [13]. Furthermore the

D

preanalytical conditions affecting insulin measurements have been carefully reviewed [14]. The

PT E

co-determination of exogenous insulin depends on the type of insulin injected and must be determined for each product and assay. C-peptide is often measured in preference of insulin,

CE

especially in the case of injection of exogenous insulin. Measurement of plasma insulin aims to assess insulin production by the beta cells in diagnosis of insulin producing tumours (insulinoma)

AC

or other causes of low blood glucose. In addition, insulin analysis is used to characterize insulin resistance or to judge when type 2 diabetics need insulin as supplement to their oral therapy [1]. Standardization and harmonization is therefore pivotal for clinical practice in diagnosing and treatment of DM. We wanted to use the Cobas e411 (Roche®) to establish traceable reference intervals for C-peptide and fasting insulin.

ACCEPTED MANUSCRIPT

Methods.

Definitions. While the definition of diabetes is the same for the WHO and the American Diabetes association

PT

(ADA) [7, 15], the WHO and the ADA definitions of prediabetes (PDM) differ from each other.

RI

The definition by ADA uses lower limits for fasting plasma glucose (FPG) and HbA1c than WHO.

SC

The following reference intervals are calculated for both non-diabetics as well as prediabetics,

NU

according to both WHO and ADA definitions (Table I).

Study population.

MA

The participants were recruited from a follow-up of the health survey “Helbred2006” (Health2006). The main study was launched in the summer of 2006 and included 3,471 randomly

D

chosen citizens (participation rate of 44.7%) living in the suburbs of Copenhagen, Denmark. Five

PT E

years later the participants in the former survey was re-invited and a total of 2,308 individuals agreed to a re-examination in between November 2011 and 2012 [16, 17]. Inclusion of the

CE

participants from whom we obtained blood samples was done consecutively, though at the end of recruitment period we tried to achieve a gender balance. Blood samples were analysed between

AC

March and August 2012. Pregnant women were excluded from participation, and users of antihistamine were asked to refrain from these medications three days prior to the examination, if possible. This also applied to use of inhalers for lung disease. The Ethics Committee of the Capital Region of Denmark (code H-3-2011-081) approved the study. The health examinations are thoroughly described by Thuesen et al. [17]..

ACCEPTED MANUSCRIPT Sample handling. All participants fasted from midnight and the following morning a venous blood sample was drawn [17]. The samples were initially stored at -20 C for one to four weeks while waiting analysis (expected to be days/at most 1-2 weeks) and subsequently transferred from -20 to -80 C

PT

during extended storage time up to six months. The blood samples were spun immediately after sampling, the plasma collected, refrigerated and stored at -20°C. Fasting insulin and –C-peptide

RI

were analyzed at Steno Diabetic Center (SDC), Gentofte, Denmark. In addition measurements of

SC

fasting glucose, HbA1c and other biochemical variables were performed. These included cholesterol and triglycerides, measured on VITROS® 5600 (Ortho Clinical Diagnostics, Raritan,

NU

NJ). Furthermore, participants’ weight, height, waist- and hip circumference was obtained. Body

MA

fat percentage was measured using a Tanita BC-420 MA segmental body composition monitor

PT E

Insulin and C-peptide assays.

D

(Tanita, Tokyo, Japan).

C-peptide and insulin were measured using a Cobas e411 (Roche Diagnostics, Mannheim, Germany) and on an AutoDELFIA (Perkin Elmer, Turku, Finland) instrument at SDC.

CE

Characteristics of both the C-peptide and fasting insulin assays on Cobas e411 and AutoDELFIA

AC

are listed in Table II.

Insulin assays.

The samples were analyzed on the Cobas e411 and on the AutoDELFIA. For the Cobas e411 analysis of insulin, the following reagents were used: cat. #12017504122, Insulin CalSet, cat. #05341787190, PreciControl Multimarker, cat. #03609979190 PreciControl Multianalyte, cat. #11731416190 and #11731416160 PreciControl. A detection interval from 0.200-1000 µU/ml or 1.39-6945 pmol/l was defined by the manufacturer [19]. The assays used for the measurements on

ACCEPTED MANUSCRIPT AutoDELFIA were B080-101 with a detection limit of 3 pmol/l and measurement interval 3-1000 pmol/l [20].

C-peptide assays.

PT

The analytical measurement range on the Cobas e411 C-peptide assay was 0.003-13.3 nmol/l or 0.010-40.0 ug/l. The following reagents were used: cat. #03184919190, C-peptide CalSet, cat.

RI

#05341787190, PreciControl Multimarker, cat. #03609979190, PreciControl Multianalyte, cat.

NU

analytical measurement range of 10-6000 pmol/l [22].

SC

#03609987190 Diluent MultiAssay [21]. The AutoDELFIA assay used was B-081-101 withan

Reference measurements.

MA

To ensure correctness of calibration, three reference pools were analyzed both on the AutoDelfia at SDC and on Cobas e411 at the Department of Laboratory Medicine and Pathology, University of

PT E

D

Minnesota, Minneapolis (UofMN), Minnesota, USA. These assays have been calibrated against the reference methods currently operated by Professor Daniel T. Stein, Albert Einstein College of

AC

Statistics

CE

Medicine, New York City, New York, USA.

The RefVal 4.11 software (Solberg, Oslo, Norway) was used to determine the reference interval according to the International Federation of Clinical Chemistry (IFCC) guidelines [23]. Reference intervals were calculated using non-parametric method (bootstrapping).

ACCEPTED MANUSCRIPT

Results. The study population A total of 2,308 participants were included in the follow-up of the population survey Health2006. Blood samples from 623 of these were used in this study. Of the 623 participants, 33 were

PT

excluded due to DM; 8 women and 25 men. From the remaining 590 participants, 85 had PDM

RI

according to the WHO definition, and 276 with reference to the ADA definition (Figure 1). There

NU

participants were 40-69 years old (mean age 54 years).

SC

was a nearly equal gender distribution (men, n = 287 (48.6 %), women, n = 303 (51.4 %)). Most

Body composition and assessment of nutritional status of the study population

MA

To characterize the participants according to nutritional status we calculated BMI and waist hip ratio (WHR). Participants who were not diabetic nor prediabetic according to the definition by

D

ADA had a median BMI 24.5 kg/m2. Mean BMI was 25 kg/m2. In summary our study population,

PT E

both men and women, were overweight and the BMI of the non-diabetic and non-prediabetic participants was slightly lower. Anthropometric indicators of body fat distribution, waist

CE

circumference (WC) and waist hip ratio (WHR) [24] are also associated with risk of diabetes and could be better indicators to discriminate the participants with diabetes from those without. Still

AC

though, both BMI, WC and WHR were all useful parameters [25]. Cut-off values of WHR vary among countries, but more variation is found for WC than WHR. In this study WHR was considered elevated when WHR  0.85 in women, and WHR  0.90 in men [26]. In women the minimum WHR was 0.68, the median value 0.82 and maximum WHR 1.03. In men the minimum WHR was 0.78, median 0.93 and maximum 1.13.

We used the intervals 20.1-24.9 % of body fat (BF) percentage for men and 30.1-34.9 % for women to define overweight; correspondently BF% ≥ 25 in men and ≥ 35 in women was defined

ACCEPTED MANUSCRIPT as obesity [24]. The overall BF% for all participants ranged from 10.2 to 50.9 with a mean BF% of 35.5 for women, equaling obesity. The male population was leaner with a median BF% below 25. Still though, the median amount of body fat found corresponds to overweight; 22.3 %. In summary, analyses of the body composition of the participant using BMI, WHR and BF% revealed

PT

that the majority of our population is either overweight or obese.

RI

Cholesterol and triglyceride levels

SC

A total blood cholesterol <5.2 mmol/l (<200 mg/dL) is considered desirable, between 5.2 and 6.2 mmol/l (200-239 mg/dL borderline high, and >6.2 mmol/l (>240 mg/dL) as high

[27].

NU

Triglycerides below 1.7 mmol/L (<150 mg/dL) is recommended by the American Heart Association, whereas 1.7-2.3 mmol/L (150-199 mg/dL) is borderline high, 2.3-5.6 (200-499 mg/dl)

MA

high and ≥5.6 (≥500 mg/dl) very high [28]. In only 41 % of non-diabetic men and 42 % of nondiabetic women total cholesterol was < 5.2 mmol/l and in 17 and 16 % it was high. The majority of

D

both non-diabetic men and women had blood triglyceride level below the cut off (78 % of men, 87

PT E

% of women). The percentage of the reference population with elevated levels of triglycerides decreased with exclusion of diabetics and prediabetics, from 30.2 to 5.8 % in women and from

CE

21.5 to 15.5 % in men. Overall, the reference population is overweight /obese and dyslipidemic,

AC

which match findings from a general Danish population survey [29].

Trueness of instrument calibration To ascertain the trueness of the calibration we exchanged three pools with the laboratory at UofMN, USA which also uses the Roche assay but have calibrated this against the reference methods currently operated by Randy Little and Daniel T. Stein [30, 31].

ACCEPTED MANUSCRIPT We found that C-peptide measurements were equivalent but 21 % higher values for insulin were determined on AutoDELFIA. We recalculated with a conversion factor of 6.0 equaling the biological activity of insulin [32] and now similar results were found (table III). Bias was greater when using the 6.945 conversion factor than 6.0: 32 versus 14 % (figure 2).

PT

C-peptide reference intervals.

RI

We calculated the reference intervals using bootstrapping as the distribution of C-peptide

NU

measurements on Cobas e411 are listed in table IV.

SC

measurements were not Gaussian (data not shown). Reference intervals for C-peptide based on

MA

Insulin reference intervals

The distribution of insulin concentrations was not Gaussian either, so again we used bootstrapping

D

to calculate the reference intervals. The results of the insulin measurements using both conversion

PT E

factors are shown in table V, VI and VII. The Cobas e411 uses a factor 6.945 for converting (µU/mL x 6.945 = pmol/L) [19] (table V). Using the conversion factor of 6.00 gave other results (table VI). We also calculated reference interval from measurements on AutoDELFIA (table VII).

CE

Detection limit of the AutoDELFIA was 3 pmol/L, however functional detection limit of 10

AC

pmol/L was used and results lower than 10 pmol/l were reported as <10 pmol/l. We calculated different reference intervals for insulin based on the AutoDELFIA measurements (table VIII). The Insulin reference intervals become narrower and upper limits decreased with exclusion of prediabetic participants from the reference population. Reference intervals for insulin on Cobas e411 determined with a conversion factor of µU/mL x 6.0 = pmol/L were much closer to the reference intervals from the AutoDELFIA measurements than calculations with conversion factor 6.945.

ACCEPTED MANUSCRIPT

Discussion

In this study we determined reference intervals for C-peptide and insulin, measured on the Roche Cobas e411 for people without DM and PDM using bootstrapping on a sample of general

PT

population of men and women 18-76 years old who were slightly overweight and hyperlipidemic.

RI

We also confirmed the previously reported problem when using the built in factory recommended

SC

conversion factor for reporting the insulin concentration in pmol/L [13, 31-34].

NU

The quality of assays is important for both the daily usage and for portability of the test results. The platform dependency of test results was illustrated with an evaluation of ten commercial

MA

insulin assays against an isotope dilution measurement procedure (isotope dilution-liquid chromatography/tandem mass spectrometry (IDMS)) calibrated by using purified recombinant

D

insulin [31]. In only four of ten methods (including the Roche assay, used in our study) ≥ 95% of

PT E

results were within the 32 % total error allowance for desirable method performance. Only the Roche and Mercodia assays showed acceptable error occurrence and in general the authors

CE

observed increasing tendency towards biases with lower concentration of insulin. We found a 20 % difference between our insulin measurements and results at the reference laboratory. This

AC

difference is attributed to an incorrect conversion factor for converting in the Cobas e411 assay. As noted previously, the Cobase411 assay uses the factor 6.945 when converting from U/ml to pmol/L. This is in disagreement with the biological activity of insulin which is 166.8 x 106 IU/mol or 6.00 nmol/IU [32]. Both the AutoDELFIA and the Cobas e411 method are calibrated traceable to the WHO IRP 66/304, a lyophilized impure preparation of human pancreatic insulin. One international unit (1 IU) of human insulin is the activity contained in 0.03846 mg of the international standard for human insulin [32]. However, as early reported the reference preparation contains impurities (salt, water, desamido insulin and ‘traces’ of proinsulin [32, 35]. While this

ACCEPTED MANUSCRIPT only has negligible importance for assigned activity it causes a major error when using the assigned mass to calculate the molar amounts of the IRP. To facilitate and standardize reporting of insulin measurements in pmol/L there is a need for having reference preparations that have been assigned values in concentration. This can be done in several ways; one possibility is simply to assign a substance concentration to the IRP 66/304. Another could be to develop a new IRP which

PT

have a substance concentration assigned from the start. One such is the newer Japanese preparation

RI

(Yomota et al., 1994). We therefore urge that actions are taken to quickly make insulin reference

NU

correctly calibrated and hence making results portable.

SC

preparations with assigned concentration available to the manufacturers so that assays can be

Regarding reference intervals for C-peptide, Little et al. [30] evaluated inter-assay (nine assays)

MA

and inter-laboratory (15 laboratories) variation and compared results to mass spectrometry method. Forty serum samples were analyzed, eight at each laboratory. They found some disagreement

D

between C-peptide results, by different laboratories and methods, primarily at high C-peptide

PT E

concentrations. They recommended calibration of C-peptide measurement to a reference method to

CE

increase comparability between laboratories.

Our reference population compares well to the characteristics of the Copenhagen General

AC

Population Study and the General Suburban Population Study in which 55.2 and 60.5 % were either overweight or obese. Also total blood cholesterol and triglycerides levels match the findings in the two bigger studies [29]. We therefore find that the population matches the average Danish population, making our reference interval applicable to the Danish and similar populations. Reference intervals have also been reported for other ethnic populations. Li et al. [36] generated a reference interval for insulin in non-diabetic Chinese men from 1,434 fasting serum insulin measurements. Their criteria for inclusion and exclusion were much broader than the Danish

ACCEPTED MANUSCRIPT survey from which samples for our study are drawn, e.g. they excluded heavy smokers.. Samples were analyzed on the Roche Cobas® 6000 system E601 Elecsys module resulting in a reference interval of 1.57-16.32 mU/L (9.4-98 pmol/L). Larsson et al. [37] reported a reference interval for insulin as 1.74 – 18.27 mU/L (10.4 - 110 pmol/L) based on measurements on 75 year old females

PT

and males with a median BMI 26.2. . This is a little narrower than our..

RI

A limitation of the current study may be that we classified participants solely based on fasting

SC

glucose and HbA1c level and not reviewed medical records. Diabetic patients with well treated disease may have normal fasting glucose and HbA1c level. Such cases were then misclassified.

NU

With this in mind we still believe that our reference intervals are valuable information for the

MA

clinician.

In summary we have determined reference intervals for insulin and C-peptide not only for a

D

nondiabetic slightly overweight population, but for a population without prediabetes, according to

PT E

both WHO and ADA definitions. This should make our reference intervals for insulin and C-

AC

CE

peptide for Roche assays widely applicable and more specific and may improve clinical practice.

ACCEPTED MANUSCRIPT Conclusion This work focused on reference interval for C-peptide and fasting insulin in non-diabetics and prediabetics, the latter according to both the WHO definition of PDM and the definition by ADA. We have generated reliable reference intervals for C-peptide which are ready for implementation,

SC

RI

PT

but for fasting insulin a recertification of standards is needed.

Acknowledgements

AC

CE

PT E

D

MA

Roche® is thanked for supplying reagents.

NU

The work in the authors’ laboratories was supported by SDC.

ACCEPTED MANUSCRIPT References

AC

CE

PT E

D

MA

NU

SC

RI

PT

[1] Eriksson SL, S. Digestionsorganen. In: Nilsson-Ehle P, editor. Laurells Klinisk Kemi i praktisk medicin. 8 ed. Lund: Studentlittteratur; 2003. [2] Steiner DF, Park SY, Stoy J, Philipson LH, Bell GI. A brief perspective on insulin production. Diabetes, obesity & metabolism 2009;11 Suppl 4:189-96. [3] Rubenstein AC, JL.;Melani,F;Steiner,DF. Secretion of proinsulin C-peptide by pancreatic B cells and its circulation in blood. Nature 1969;224:697-9. [4] Marques RGF, M. J.; Rogers, J.; . C-Peptide - Much More Than a Byproduct of Insulin Biosynthesis. Pancreas 2004;29:231-8. [5] Kruszynska YT, Home PD, Hanning I, Alberti KG. Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia 1987;30:16-21. [6] Diagnosis and Classification of Diabetes Mellitus: Diabetes Care, American Diabetes Association; 2014. [7] (2) Classification and diagnosis of diabetes. Diabetes care 2015;38 Suppl:S8-S16. [8] Diagnosis and classification of diabetes mellitus. Diabetes care 2014;37 Suppl 1:S81-90. [9] O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obesity reviews : an official journal of the International Association for the Study of Obesity 2015;16:1-12. [10] Deedwania PC, Gupta R. Management issues in the metabolic syndrome. The Journal of the Association of Physicians of India 2006;54:797-810. [11] Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. The Journal of clinical investigation 1960;39:1157-75. [12] Sapin R. Insulin immunoassays: fast approaching 50 years of existence and still calling for standardization. Clinical chemistry 2007;53:810-2. [13] Staten MA, Stern MP, Miller WG, Steffes MW, Campbell SE, Insulin Standardization W. Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care. Diabetes care 2010;33:205-6. [14] Sapin R. Insulin assays: previously known and new analytical features. Clinical laboratory 2003;49:113-21. [15] Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia - Report of a WHO/IDF Consultation. Geneva, Switzerland: World Health Organization - International Diabetes Federation; 2006. [16] Gonzalez-Quintela A, Dam Laursen AS, Vidal C, Skaaby T, Gude F, Linneberg A. IgE antibodies to alpha-gal in the general adult population: relationship with tick bites, atopy, and cat ownership. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2014;44:1061-8. [17] Thuesen BH, Cerqueira C, Aadahl M, Ebstrup JF, Toft U, Thyssen JP, Fenger RV, Hersoug LG, Elberling J, Pedersen O, Hansen T, Johansen JD, Jorgensen T, Linneberg A. Cohort Profile: the Health2006 cohort, research centre for prevention and health. International journal of epidemiology 2014;43:568-75. [18] Horwitz A, Skaaby T, Karhus LL, Schwarz P, Jorgensen T, Rumessen JJ, Linneberg A. Screening for celiac disease in Danish adults. Scand J Gastroenterol 2015;50:824-31. [19] COBAS Kit-insert Insulin: Roche Diagnostics; 2011. [20] AutoDELFIA Insulin Kit insert B080-101. Turku, Finland: PerkinElmer Life and Analytical Sciences; 2003. [21] C-peptide - Connecting peptide. Mannhein, Germany: Roche Diagnostics GmbH; 2011. [22] AutoDELFIA C-peptide Kit insert B081-101. Turku, Finland: PerkinElmer Life and Analytical Sciences; 2003.

ACCEPTED MANUSCRIPT

AC

CE

PT E

D

MA

NU

SC

RI

PT

[23] Solberg HE. RefVal: a program implementing the recommendations of the International Federation of Clinical Chemistry on the statistical treatment of reference values. Comput Methods Programs Biomed 1995;48:247-56. [24] Gomez-Ambrosi J, Silva C, Galofre JC, Escalada J, Santos S, Gil MJ, Valenti V, Rotellar F, Ramirez B, Salvador J, Fruhbeck G. Body adiposity and type 2 diabetes: increased risk with a high body fat percentage even having a normal BMI. Obesity 2011;19:1439-44. [25] Qiao Q, Nyamdorj R. Is the association of type II diabetes with waist circumference or waistto-hip ratio stronger than that with body mass index? European journal of clinical nutrition 2010;64:30-4. [26] Waist Circumference and Waist-Hip Ratio - Report of a WHO Expert Consultation - Geneva 8-11 December 2008. Geneva, Switzerland: World Health Organization; 2011. [27] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report: National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health; 2002. [28] Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, American Heart Association Clinical Lipidology T, Prevention Committee of the Council on Nutrition PA, Metabolism, Council on Arteriosclerosis T, Vascular B, Council on Cardiovascular N, Council on the Kidney in Cardiovascular D. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-333. [29] Bergholdt HK, Bathum L, Kvetny J, Rasmussen DB, Moldow B, Hoeg T, Jemec GB, BernerNielsen H, Nordestgaard BG, Ellervik C. Study design, participation and characteristics of the Danish General Suburban Population Study. Danish medical journal 2013;60:A4693. [30] Little RR, Rohlfing CL, Tennill AL, Madsen RW, Polonsky KS, Myers GL, Greenbaum CJ, Palmer JP, Rogatsky E, Stein DT. Standardization of C-peptide measurements. Clinical chemistry 2008;54:1023-6. [31] Miller WG, Thienpont LM, Van Uytfanghe K, Clark PM, Lindstedt P, Nilsson G, Steffes MW, Insulin Standardization Work G. Toward standardization of insulin immunoassays. Clinical chemistry 2009;55:1011-8. [32] Volund A, Brange J, Drejer K, Jensen I, Markussen J, Ribel U, Sorensen AR, Schlichtkrull J. In vitro and in vivo potency of insulin analogues designed for clinical use. Diabetic medicine : a journal of the British Diabetic Association 1991;8:839-47. [33] Heinemann L. Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care: response to Staten et al. Diabetes care 2010;33:e83; author reply e4. [34] Marcovina S, Bowsher RR, Miller WG, Staten M, Myers G, Caudill SP, Campbell SE, Steffes MW, Insulin Standardization W. Standardization of insulin immunoassays: report of the American Diabetes Association Workgroup. Clinical chemistry 2007;53:711-6. [35] WHO Reference Reagent Insulin, Human For Immunoassay, 1st International Reference Preparation NIBSC code: 66/304 Potters Bar, Hertfordshire, United Kingdom: National Institute for Biological Standards and Control; 2013 16/04/2013. [36] Li S, Huang S, Mo ZN, Gao Y, Yang XB, Chen XJ, Zhao JM, Qin X. Generating a reference interval for fasting serum insulin in healthy nondiabetic adult Chinese men. Singapore medical journal 2012;53:821-5. [37] Larsson A, Stridsberg M, Lind L. Reference values for fasting insulin in 75 year old females and males. Clin Biochem 2013;46:1125-7.

ACCEPTED MANUSCRIPT

Tables Table I: The definitions of pre-diabetes and diabetes used define the groups of the participants Fasting plasma glucose (FPG) of ≥ 7 mmol/L and/or HbA1c ≥ 6.5 % / ≥ 48 mmol/L.

Prediabetes (WHO):

FPG ≥ 6.1 mmol/L and/or HbA1c ≥ 6.0 % / ≥ 42 mmol/L [15].

Prediabetes (ADA):

FPG ≥ 5.6 mmol/L and/or HbA1c ≥ 5.7 % [7].

AC

CE

PT E

D

MA

NU

SC

RI

PT

Diabetes:

ACCEPTED MANUSCRIPT Table II: Analytical characteristics of the insulin and C-peptide assays The characteristics are those obtained during the study and analysis period

Asssay

Insulin

Traceability

Analytical imprecision, SDC

WHO International Reference

130

3.0

Diagnostics®

Reagent, IRR 84/510

1100

2.4

2575

3.6

33

5.0

128

4.4

739

3.9

113

3.7

1092

2.8

2489

2.3

21

7.0

74

4.7

301

3.8

Cobas e411, Roche

WHO IRP 66/304

WHO IRP 66/304

CE

PT E

D

MA

NU

AutoDELFIA, Perkin Elmer®

RI

WHO 84/510

SC

AutoDELFIA, Perkin Elmer®

AC

Insulin

CV %

Cobas e411, Roche

Diagnostics®

C-peptide

Level, pmol/L

PT

C-peptide

Manufacturer

ACCEPTED MANUSCRIPT Table III: Correctness of the calibration Pool

Low Middle High

C-peptide (UofMN) (pmol/L)

C-peptide (SDC) (pmol/L)

Insulin (UofMN) (pmol/L)

126 1060 2510

131 1110 2614

27 107 614

Insulin (SDC) (pmol/L) CF 6.0 29 111 641

Insulin (SDC) (pmol/L) CF 6.945 33 129 742

AC

CE

PT E

D

MA

NU

SC

RI

PT

SDC and UofMN reported similar results for C-peptide for all calibration levels with duplicate measurements of each sample. Using the default conversion factor listed in the Cobas insert kit yielded greater values at SDC at all levels. A conversion factor of 6.00 almost eliminated this difference.

ACCEPTED MANUSCRIPT Table IV. Reference intervals for C-peptide (Cobas e411) The C-peptide reference intervals depend on whether prediabetic populations are included or not. With exclusion of prediabetic participants the reference interval narrows

2,5% limit (90% CI)

97,5% limit (90% CI)

N

Without diabetes

379 (372-414)

1631 (1466-1713)

590

Without prediabetes (WHO)

376 (369-409)

1479 (1311-1649)

505

Without prediabetes (ADA)

372 (341-390)

1299 (1219-1479)

314

AC

CE

PT E

D

MA

NU

SC

RI

PT

C-peptide (pmol/L)

ACCEPTED MANUSCRIPT Table V. Insulin reference intervals (factor 6.945) (Cobas e411) 2.5% limit (90%

97.5% limit (90% CI),

N

CI), pmol/L

pmol/L

Without diabetes

19 (16-21)

161 (152-186)

590

Without prediabetes (WHO)

16 (16-20)

147 (135-174)

505

Without prediabetes (ADA)

16 (15-19)

135 (113-153)

314

RI

PT

Insulin (pmol/L)

2.5% limit (90% CI),

97.5% limit (90% CI),

pmol/L

pmol/L

16 (14-18)

Without prediabetes (WHO)

14 (14-17)

Without prediabetes (ADA)

14 (13-16)

140 (132-161)

n

590

126 (117-141)

505

117 (98-132)

304

MA

Without diabetes

NU

Insulin (pmol/L)

SC

Table VI: insulin reference interval (factor 6.0) (Cobas e411)

Without diabetes Without prediabetes (WHO)

AC

CE

Without prediabetes (ADA)

2.5% limit (90% CI),

97.5% limit (90% CI),

pmol/L

pmol/L

≤10 (≤10)

120 (104-142)

590

≤10 (≤10)

99 (92-117)

505

≤10 (≤10)

86 (79-96)

314

PT E

Insulin (pmol/L)

D

Table VII: Insulin reference interval (AutoDELFIA) n

ACCEPTED MANUSCRIPT

Figures Health2006

PT

Health2006 follow-up, n = 2,308

RI

Participants eligible for current study, n = 623

Excluded due to diabetes, n = 33

SC

Participants without diabetes, n = 590

Prediabetics according to ADA, n = 276

MA

No prediabetes according to ADA, n = 314

NU

Prediabetics according to WHO, n = 85

No prediabetes according to WHO, n = 505

Figure 1: Flow-chart outlining the study design and number of participants used for calculating the reference intervals.

AC

CE

PT E

D

With reference to definitions listed elsewhere, participants were grouped/excluded according to their FPG and HbA1c-level. Of the 590 participants without DM, almost half of them (47 %) had PDM with reference to ADA and only 85 (14 %) according to WHO.

ACCEPTED MANUSCRIPT

Insulin - Cobas, CF 6.945 (pmol/L) Y = 1.316*X + 3.575

Equation

Insulin - Cobas, CF 6.00 (pmol/L) Y = 1.136*X + 3.145

500

( p m o l/L )

400

PT

In s u lin - C o b a s , C F 6 .9 4 5 ( p m o l/L )

300

RI

200

100

0 100

200

300

In s u lin - A u to D E L F IA

500

MA

( p m o l/L )

400

NU

0

SC

In s u llin (p m o l/L )

In s u lin - C o b a s , C F 6 .0 0

Figure 2: Method comparison between AutoDELFIA and Cobas e411 plasma insulin measurements. Plasma insulin measurements generated using the AutoDELFIA were compared to those obtained on the

D

Cobas platform using the conversion factor (CF) 6.945 (32 % higher results) or a CF of 6.00 (14 % higher

AC

CE

PT E

results).